

Company registration number 417513 (Republic of Ireland)

**SANDYMOUNT PHARMACY LIMITED
ABRIDGED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2025**

SANDYMOUNT PHARMACY LIMITED

COMPANY INFORMATION

Director	Grainne Murphy
Secretary	Dualta Moore
Company number	417513
Registered office	1A Sandymount Green Sandymount Dublin 4
Accountants	PKF Brenson Lawlor Argyle Square Morehampton Road Donnybrook Dublin 4 D04 W9W7
Business address	1A Sandymount Green Sandymount Dublin 4
Bankers	Allied Irish Bank Plc 98 Sandymount Road Dublin 4 Bank of Ireland Ballsbridge Dublin 4
Solicitors	O'Donnell Sweeney One Earlsfort Centre Earlsfort Terrace Dublin 2

SANDYMOUNT PHARMACY LIMITED

CONTENTS

	Page
Director's responsibilities statement	1
Director's declaration	2
Statement of financial position	4 - 5
Notes to the financial statements	6 - 11

SANDYMOUNT PHARMACY LIMITED

DIRECTOR'S RESPONSIBILITIES STATEMENT

FOR THE YEAR ENDED 31 MAY 2025

The director is responsible for preparing the Director's Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the director to prepare financial statements for each financial year. Under that law, the director has elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (Generally accepted Accounting Practice in Ireland) issued by the Financial Reporting Council. Under company law, the director must not approve the financial statements unless she is satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for that financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the director is required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The director is responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Director's Report comply with the Companies Act 2014. She is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

By order of the board

Signed by:

4CCD2294465B408...
Dualta Moore
Secretary

Signed by:

57834845231E49D...
Grainne Murphy
Director

2 September 2025

SANDYMOUNT PHARMACY LIMITED

DIRECTOR'S DECLARATION ON UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MAY 2025

In relation to the financial statements which comprise the Statement of Comprehensive Income, the Statement Of Financial Position and the related notes:

- The director approves these financial statements and confirms that she is responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgments underlying them. They have been prepared on the going concern basis on the grounds that the company will continue in business.
- The director confirms that she has made available to JPA Brenson Lawlor all the company's accounting records and provided all the information necessary for the compilation of the financial statements.
- The director confirms that to the best of her knowledge and belief, the accounting records reflect all transactions of the company for the year ended 31 May 2025.

By order of the board

Signed by:

4CCD2294465B408...
Dualta Moore
Secretary

Signed by:

57834845231E49D...
Grainne Murphy
Director

2 September 2025

SANDYMOUNT PHARMACY LIMITED

REPORT TO THE DIRECTOR ON THE PREPARATION OF THE UNAUDITED STATUTORY ACCOUNTS OF SANDYMOUNT PHARMACY LIMITED

In accordance with the engagement letter dated 2 September 2025, and in order to assist you to fulfil your duties under the Companies Act 2014, we have compiled the financial statements of the company for the year ended 31 May 2025 which comprise the statement of comprehensive income, the statement of financial position and the related notes from the accounting records and information and explanations you have given to us.

As a practising member firm of the Institute of Certified Public Accountants in Ireland, we are subject to its ethical and other professional requirements.

This report is made solely to the Board of Directors of Sandymount Pharmacy Limited, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the financial statements of Sandymount Pharmacy Limited and state those matters that we have agreed to state to the Board of Directors of Sandymount Pharmacy Limited, as a body, in this report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Sandymount Pharmacy Limited and its Board of Directors as a body, for our work or for this report.

It is your duty to ensure that Sandymount Pharmacy Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Sandymount Pharmacy Limited. You consider that Sandymount Pharmacy Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Sandymount Pharmacy Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

PKF Brenson Lawlor
Chartered Accountants
Argyle Square
Morehampton Road
Donnybrook
Dublin 4
D04 W9W7
2 September 2025

SANDYMOUNT PHARMACY LIMITED

STATEMENT OF FINANCIAL POSITION

AS AT 31 MAY 2025

	Notes	2025		2024	
		€	€	€	€
Fixed assets					
Intangible assets	5		740,000		740,000
Tangible assets	6		28,162		34,081
			<u>768,162</u>		<u>774,081</u>
Current assets					
Stocks	7	50,108		48,890	
Debtors	8	130,200		114,231	
Cash at bank and in hand		9,591		8,744	
			<u>189,899</u>	<u>171,865</u>	
Creditors: amounts falling due within one year	9	(220,363)		(200,773)	
Net current liabilities			<u>(30,464)</u>		<u>(28,908)</u>
Total assets less current liabilities			737,698		745,173
Creditors: amounts falling due after more than one year	10		(17,612)		(63,377)
Net assets			<u>720,086</u>		<u>681,796</u>
Capital and reserves					
Called up share capital presented as equity			100		100
Profit and loss reserves	11		719,986		681,696
Total equity			<u>720,086</u>		<u>681,796</u>

SANDYMOUNT PHARMACY LIMITED

STATEMENT OF FINANCIAL POSITION (CONTINUED)

AS AT 31 MAY 2025

I, as director of Sandymount Pharmacy Limited, state that:

(a) The company is availing itself of the exemption from audit provided for by Chapter 15 of Part 6 of the Companies Act 2014.

(b) The company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied.

(c) The shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2).

(d) The director acknowledges the obligations of the company, under the Companies Act 2014:

(i) to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a year; and

(ii) to otherwise comply with the provisions of this Act relating to financial statements so far as they are applicable to the company.

(e) The company has relied on the specified exemption contained in section 352 Companies Act 2014; the company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with Financial Reporting Standard 102 'The Financial Statement Reporting Standard applicable in the UK and Republic of Ireland'.

The financial statements were approved and signed by the director and authorised for issue on 2 September 2025

Signed by:



57834845231E49D...

Grainne Murphy

Director

SANDYMOUNT PHARMACY LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MAY 2025

1 Accounting policies

Company information

Sandymount Pharmacy Limited is a private company limited by shares domiciled and incorporated in the Republic of Ireland. The registered office is 1A Sandymount Green, Sandymount, Dublin 4 and its company registration number is 417513.

1.1 Accounting convention

These financial statements have been prepared on a going concern basis and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102"), as adapted by Section 1A of FRS 102, and the requirements of the Companies Act 2014.

The financial statements are prepared in euros, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest €.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2 Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

1.3 Intangible fixed assets - goodwill

Acquired goodwill is written off in equal annual instalments over its estimated useful economic life. Impairment reviews are carried out and to the extent that the carrying amount exceeds the recoverable amount, the goodwill is written down and the impairment loss is recognised in the profit and loss account.

1.4 Tangible fixed assets

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures, fittings & equipment	20%
Computer equipment	20%
Motor vehicles	20%

1.5 Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset is estimated to be less than its carrying amount, the carrying amount of the asset is reduced to its recoverable amount.

1.6 Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell.

Stocks held for distribution at no or nominal consideration are measured at the lower of replacement cost and cost, adjusted where applicable for any loss of service potential.

SANDYMOUNT PHARMACY LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MAY 2025

1 Accounting policies

(Continued)

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.7 Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.8 Financial instruments

The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's statement of financial position when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest.

1.9 Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.10 Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

SANDYMOUNT PHARMACY LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MAY 2025

1 Accounting policies (Continued)

1.11 Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

1.12 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.13 Leases

As lessee

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessees. All other leases are classified as operating leases.

Assets held under finance leases are recognised as assets at the lower of the assets fair value at the date of inception and the present value of the minimum lease payments. The related liability is included in the statement of financial position as a finance lease obligation. Lease payments are treated as consisting of capital and interest elements. The interest is charged to profit or loss so as to produce a constant periodic rate of interest on the remaining balance of the liability.

2 Operating profit

	2025	2024
	€	€
Operating profit for the year is stated after charging:		
Depreciation of tangible fixed assets	9,644	9,895
	<u>9,644</u>	<u>9,895</u>

3 Employees

The average monthly number of persons (including directors) employed by the company during the year was:

	2025	2024
	Number	Number
Total	6	6
	<u>6</u>	<u>6</u>

4 Director's remuneration

	2025	2024
	€	€
Remuneration for qualifying services	89,640	96,072
	<u>89,640</u>	<u>96,072</u>

SANDYMOUNT PHARMACY LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MAY 2025

5 Intangible fixed assets

	Goodwill
	€
Cost	
At 1 June 2024 and 31 May 2025	1,799,703
Amortisation and impairment	
At 1 June 2024 and 31 May 2025	1,059,703
Carrying amount	
At 31 May 2025	740,000
At 31 May 2024	740,000

6 Tangible fixed assets

	Fixtures, fittings & equipment	Computer equipment	Motor vehicles	Total
	€	€	€	€
Cost				
At 1 June 2024	143,211	24,784	41,680	209,675
Additions	1,200	2,525	-	3,725
At 31 May 2025	144,411	27,309	41,680	213,400
Depreciation and impairment				
At 1 June 2024	142,457	22,717	10,420	175,594
Depreciation charged in the year	430	878	8,336	9,644
At 31 May 2025	142,887	23,595	18,756	185,238
Carrying amount				
At 31 May 2025	1,524	3,714	22,924	28,162
At 31 May 2024	754	2,067	31,260	34,081

7 Stocks

	2025	2024
	€	€
Finished goods and goods for resale	50,108	48,890

SANDYMOUNT PHARMACY LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MAY 2025

8 Debtors	2025	2024
Amounts falling due within one year:	€	€
Trade debtors	30,562	31,134
Corporation tax recoverable	11,258	15,258
Other debtors	77,950	60,200
Prepayments	10,430	7,639
	<u>130,200</u>	<u>114,231</u>
	<u><u>130,200</u></u>	<u><u>114,231</u></u>
9 Creditors: amounts falling due within one year	2025	2024
Notes	€	€
Amounts owed to credit institutions	77,376	60,202
Obligations under finance leases	7,549	6,951
Trade creditors	83,000	63,561
Other creditors including tax and social insurance	31,799	49,581
Accruals	20,639	20,478
	<u>220,363</u>	<u>200,773</u>
	<u><u>220,363</u></u>	<u><u>200,773</u></u>
10 Creditors: amounts falling due after more than one year	2025	2024
Notes	€	€
Amounts owed to credit institutions	-	41,179
Obligations under finance leases	17,612	22,198
	<u>17,612</u>	<u>63,377</u>
	<u><u>17,612</u></u>	<u><u>63,377</u></u>
11 Profit and loss reserves	2025	2024
	€	€
At the beginning of the year	681,696	672,322
Adjusted balance	681,696	672,322
Profit for the year	38,290	9,374
At the end of the year	<u>719,986</u>	<u>681,696</u>
	<u><u>719,986</u></u>	<u><u>681,696</u></u>
12 Events after the reporting date		

There were no post balance sheet events which would materially affect the financial statements which require disclosure under FRS 102.

SANDYMOUNT PHARMACY LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) ***FOR THE YEAR ENDED 31 MAY 2025***

13 Directors' transactions

At 31 May 2025 Grainne Murphy owed €77,950 to Sandymount Pharmacy Ltd. (2024: €60,200)

14 Parent company

Grainne Murphy is the ultimate controlling party.

15 Approval of financial statements

The director approved the financial statements on 2 September 2025.